Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. The CHALLENGE trial sought to address this knowledge gap. NEJM Editorial Fellow Sarah Gorey, MB (Sarah Gorey), explains in this 60-Second Journal Club video. Read the full trial results:

NEJM's profile picture

NEJM

1,003,851 subscribers

12,384 Aufrufe • vor 1 Jahr •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

2 Kommentare

Profilbild von Dr. Mahesh Banda
Dr. Mahesh Bandavor 1 Jahr

@sarah_gorey First step: Case control studies with family history of cancer and age of presentation with physical fitness as one of the major parameter, might determine the next step for the cohort studies.

Profilbild von Naveen Sankar S
Naveen Sankar Svor 1 Jahr

🚴‍♂️ Higher cardiorespiratory fitness may reduce dementia risk, even for those with a genetic predisposition! A study links high fitness to better cognition and delayed dementia onset by over 1.4 years. 🔗 #DementiaPrevention #Fitness #BrainHealth 🧠

Ähnliche Videos

In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary:
1:48

In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary:

NEJM

10,641 Aufrufe • vor 1 Jahr

Pharmacologic treatment options for cancer cachexia are limited. NEJM Editorial Fellow Harleen Marwah, MD, summarizes research on the safety and efficacy of the monoclonal antibody ponsegromab for treating cancer cachexia. Read the full trial results:
1:40

Pharmacologic treatment options for cancer cachexia are limited. NEJM Editorial Fellow Harleen Marwah, MD, summarizes research on the safety and efficacy of the monoclonal antibody ponsegromab for treating cancer cachexia. Read the full trial results:

NEJM

16,522 Aufrufe • vor 1 Jahr

Observational evidence is conflicting on whether the sex of blood donors affects recipient outcomes. New findings from a randomized trial are summarized in this short video.
1:51

Observational evidence is conflicting on whether the sex of blood donors affects recipient outcomes. New findings from a randomized trial are summarized in this short video.

NEJM

42,725 Aufrufe • vor 3 Jahren

Induction medication for emergency intubation — does the choice matter? NEJM Editorial Fellow Katerina Lin, MD, explains a randomized trial to determine the effects of ketamine vs. etomidate for induction of anesthesia during emergency tracheal intubation. Full RSI trial results:
1:19

Induction medication for emergency intubation — does the choice matter? NEJM Editorial Fellow Katerina Lin, MD, explains a randomized trial to determine the effects of ketamine vs. etomidate for induction of anesthesia during emergency tracheal intubation. Full RSI trial results:

NEJM

21,895 Aufrufe • vor 3 Monaten

NEJM Editorial Fellow Harleen Marwah, MD (Harleen Marwah, MD, MS), summarizes the API-CAT trial.
2:01

NEJM Editorial Fellow Harleen Marwah, MD (Harleen Marwah, MD, MS), summarizes the API-CAT trial.

NEJM

11,385 Aufrufe • vor 1 Jahr

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.
1:30

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.

NEJM

98,938 Aufrufe • vor 1 Jahr

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:
1:14

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

NEJM

19,398 Aufrufe • vor 7 Monaten

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology
1:23

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial investigating the effectiveness of shunt surgery for idiopathic normal-pressure hydrocephalus. Read the full results for free: #neurology

NEJM

56,721 Aufrufe • vor 5 Monaten

Monoclonal gammopathy of undetermined significance (MGUS) is a common, asymptomatic plasma-cell disorder in older adults that can progress to cancer or systemic illness. NEJM Editorial Fellow Katerina Lin, MD, shares some key points from a review published in October. Read the full article:
1:18

Monoclonal gammopathy of undetermined significance (MGUS) is a common, asymptomatic plasma-cell disorder in older adults that can progress to cancer or systemic illness. NEJM Editorial Fellow Katerina Lin, MD, shares some key points from a review published in October. Read the full article:

NEJM

16,361 Aufrufe • vor 5 Monaten

Drs. Greg Katz, MD, Shreya P. Trivedi MD, MHPE & Abby Schubach MD discuss the NordICC trial: Does colonoscopy reduce colorectal cancer incidence? Hear more in the latest episode of Beyond Journal Club, a CORE IM in collaboration with NEJM Group:
0:50

Drs. Greg Katz, MD, Shreya P. Trivedi MD, MHPE & Abby Schubach MD discuss the NordICC trial: Does colonoscopy reduce colorectal cancer incidence? Hear more in the latest episode of Beyond Journal Club, a CORE IM in collaboration with NEJM Group:

NEJM

14,595 Aufrufe • vor 2 Jahren

Ondansetron is often prescribed at ED discharge for children seen for gastroenteritis to reduce further symptoms, but evidence to support doing so is limited. A new trial investigates whether postdischarge ondansetron is beneficial. Full trial results:
1:47

Ondansetron is often prescribed at ED discharge for children seen for gastroenteritis to reduce further symptoms, but evidence to support doing so is limited. A new trial investigates whether postdischarge ondansetron is beneficial. Full trial results:

NEJM

14,351 Aufrufe • vor 11 Monaten

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:
1:18

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

47,782 Aufrufe • vor 6 Monaten

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:
1:30

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:

NEJM

32,367 Aufrufe • vor 7 Monaten

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:
1:24

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free:

NEJM

46,802 Aufrufe • vor 8 Monaten

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:
1:22

In the latest video in our partnership with Dr. Glaucomflecken, the INSEMA trial investigating axillary surgery in breast cancer is explained. Access the article for free:

NEJM

130,645 Aufrufe • vor 1 Jahr

How is cumulative medical imaging in childhood associated with cancer risk? NEJM Editorial Fellow Katerina Lin, MD, summarizes a recent retrospective cohort study involving 3 million children. Read the full study:
1:48

How is cumulative medical imaging in childhood associated with cancer risk? NEJM Editorial Fellow Katerina Lin, MD, summarizes a recent retrospective cohort study involving 3 million children. Read the full study:

NEJM

22,502 Aufrufe • vor 3 Monaten

In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue. Full trial results and Research Summary:
1:16

In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue. Full trial results and Research Summary:

NEJM

15,115 Aufrufe • vor 3 Monaten

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:
1:06

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,312 Aufrufe • vor 2 Monaten